Amgen-AstraZeneca Drug Combo Dramatically Boosts Survival in Aggressive Lung Cancer
A groundbreaking drug combination by Amgen and AstraZeneca has delivered an unprecedented 58% reduction in the risk of death for patients with extensive-stage small cell lung cancer (ES-SCLC), a notoriously aggressive form of the disease. The pairing of Amgen's Imdelltra (tarlatamab-dlle) and AstraZeneca's Imfinzi (durvalumab), used as a first-line maintenance treatment, extended median overall survival by more than eight months, to 21.1 months, compared to 12.7 months for Imfinzi alone. This landmark data, presented at the European Society for Medical Oncology (ESMO) Congress 2026, marks a significant leap forward in a cancer where advancements have historically been hard-won.











